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n the last decade, our understanding of Alzheimer's disease has advanced considerably. Thanks to evolving biomarker research, it is now recognized that a preclinical stage occurs before the occurrence of symptoms. 1 This preclinical phase has become the focus of considerable research efforts as early intervention is likely to offer the best chances of a cure. To date, very little clinical evidence is available in the effectiveness of drugs in this stage of the disease.
In an expert interview, Dr Farlow discusses the concept of preclinical Alzheimer's disease and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial, which is investigating drugs to slow or prevent disease progression in autosomal dominant Alzheimer's disease families.
Q. How is preclinical Alzheimer's disease defined?
Until recently, Alzheimer's dementia was defined primarily by clinical criteria, characterized by deficits in memory and other cognitive functions that progressively impair activities of daily living. Clinical and laboratory studies demonstrate no other cause for these symptoms and there is no evidence of other neurodegenerative disease that could impair cognition. Over the last decades it has been recognized that, prior to developing dementia, people go through a phase called mild cognitive impairment, which is a pre-dementia but not preclinical phase. 
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A large amount of research has found that there is a very early stage where no biomarkers are detectable but pathological changes in the brain are occurring due to biological processes that predispose to, or are the earliest steps on the road to, Alzheimer's dementia. 3 It is believed that these changes then progress to a stage that involves deposition of betaamyloid in the cortex of the brain. 4 Beta amyloid is the chief component of plaques in Alzheimer's disease. have not been demonstrated to be effective in patients with established sporadic Alzheimer's disease with mild cognitive impairment or mild dementia. 9 As a result, the third arm of the study was discontinued.
Another finding from trials suggests that the original mABs chosen were probably administered at too low a dose to effectively engage the target, and therefore study protocols have been amended to give higher, hopefully more effective doses.
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The second-generation trial will test two interventions against placebo.
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One will be a drug targeting Tau, which is associated with the formation of neurofibrillary tangles, one of the characteristic findings of Alzheimer's disease; the other has not yet been chosen. The population will be primarily younger, very early preclinical Alzheimer's disease patients who are carrying the dominantly inherited genes for Alzheimer's disease. The trial uses evidence that has accumulated from the DIAN-TU trial and is applying a model of disease progression using biomarkers. A composite outcome measure has been developed that is very sensitive, even in preclinical patients. It is recognized that, in these trials, initial dosage assignments, and how a different drug is administered, may need to change over time, and an algorithm is being built into the trial that allows adjustment. The trial is designed to last 4 years but will maintain a blinded collection of data until the last patient is treated. This aim is to maximize the probability of determining whether a given drug is beneficial in these patients in particular and in Alzheimer's disease in general. q
